Frontlight ResearchEarly access
Taking people in BelgiumPhase 1
Small-dose injection into melanoma tumors alongside anti-PD1 treatment
Tests a small injected dose directly into tumors in adults with advanced melanoma.
Key facts
- Who runs it
- UZ Leuven
- Where
- Leuven, BelgiumSee the site
- Trial code
- Registry title
- INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 4 people, planned
- Started
- 18 Feb 2025
- Expected to end
- 4 Sept 2028
- Type of study
- Interventional
- Record updated
- 18 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced malignant melanoma who receive anti-PD1 therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced malignant melanoma.
- Earlier treatment
- People receive anti-PD1 therapy.
Where in Belgium
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Small-dose injection into melanoma tumors alongside anti-PD1 treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 June 2026